HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a 'Buy' rating on Olema Pharmaceuticals (NASDAQ:OLMA) and raises the price target from $22 to $28.
September 05, 2023 | 4:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Olema Pharmaceuticals' price target has been raised from $22 to $28 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Olema Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100